Cytotoxicity, Retention, and Anti-inflammatory Effects of a CeO
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
15
10
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Both cerium oxide (CeOx) nanoparticles and mefenamic acid (MFA) are known anti-inflammatory agents with hepatoprotective properties and are therefore prescribed for one of the major diseases in the world, nonalcoholic fatty liver disease (NAFLD). To study the potential cytotoxicity and anti-inflammatory effects as well as drug retention of a potential therapeutic CeOx/MFA supramolecular complex, a well-standardized hepatic (HepG2) spheroid model was used. Results showed that the highest cytotoxicity for the CeOx/MFA supramolecular complex was found at 50 μg/mL, while effective doses of 0.1 and 1 μg/mL yielded a significant decrease of TNF-α and IL-8 secretion. Time-resolved analysis of HepG2 spheroids revealed a spatiotemporal distribution of the supramolecular complex and limited clearance from the internal microtissue over a period of 8 days in cultivation. In summary, our results point at rapid uptake, distribution, and biostability of the supramolecular complex within the HepG2 liver spheroid model as well as a significant anti-inflammatory response at noncytotoxic levels.
Identifiants
pubmed: 33615164
doi: 10.1021/acsptsci.0c00170
pmc: PMC7887746
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101-106Informations de copyright
© 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): Work in this paper was partially supported by funding from Farmak JSC who also produced the supramolecular complex in cooperation with the Institute for Scintillation Materials. All experiments were performed by the Technical University of Vienna in cooperation with SAICO Biosystems.
Références
Free Radic Biol Med. 2005 Mar 15;38(6):755-62
pubmed: 15721986
Int J Mol Sci. 2013 Jun 05;14(6):11963-80
pubmed: 23739675
J Pharm Biomed Anal. 1998 Dec;18(4-5):899-905
pubmed: 9919995
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Drug Dev Ind Pharm. 2000 May;26(5):477-87
pubmed: 10789059
Eur J Pharm Sci. 2020 Mar 1;144:105213
pubmed: 31926941
Sci Rep. 2019 Mar 19;9(1):4863
pubmed: 30890741
Therap Adv Gastroenterol. 2010 Mar;3(2):121-37
pubmed: 21180596
Methods Mol Biol. 2019;2054:263-282
pubmed: 31482461
Subcell Biochem. 2007;42:3-27
pubmed: 17612044
MethodsX. 2018 Jul 23;5:781-787
pubmed: 30094205
World J Gastroenterol. 2012 May 21;18(19):2300-8
pubmed: 22654421
World J Gastroenterol. 2017 Jun 14;23(22):3954-3963
pubmed: 28652650
ACS Nano. 2013 Dec 23;7(12):10582-96
pubmed: 24266731
J Am Assoc Lab Anim Sci. 2015 Mar;54(2):120-32
pubmed: 25836957
Bioeng Transl Med. 2016 Sep 19;1(3):252-266
pubmed: 29313016
Adv Mater. 2013 Jul 26;25(28):3888-98
pubmed: 24048975
Adv Healthc Mater. 2013 Feb;2(2):297-301
pubmed: 23184583
J Hepatol. 2016 Mar;64(3):691-8
pubmed: 26519601
Sci Rep. 2019 Feb 22;9(1):2595
pubmed: 30796322
Int J Clin Exp Med. 2015 Dec 15;8(12):22477-83
pubmed: 26885230
J Clin Invest. 2001 Apr;107(7):813-22
pubmed: 11285300
BMC Gastroenterol. 2012 Mar 01;12:20
pubmed: 22380754
Sci Rep. 2019 Sep 6;9(1):12848
pubmed: 31492960